Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Tvardi TherapeuticsTvardi Therapeutics to Participate in Upcoming Investor EventsTvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events:
- Form-8.3 ADVANCED MEDICAL SOLUTIONS GROUP PLC - 25 08 2026 - (CGWL)FORM 8.3
- HepaRegeniX Receives Orphan Drug Designation for Darizmetinib for the Prevention of Post-Hepatectomy Liver FailureU.S. FDA Orphan Drug Designation underscores darizmetinib’s potential to address a significant unmet need following liver resection
- Global Spatial Computing Market Forecast to Reach $662.99 Billion by 2035Key opportunities include software, mixed reality and healthcare applications, especially immersive medical training. Growth potential also lies in integrated spatial data, digital workspace and location-aware platforms, with expansion in Asia Pacific and the Middle East.
- Cell and Gene Therapy CDMO Market Reaches USD 3.71 Billion in 2025 as Clinical Pipelines and Manufacturing Demand ExpandExpanding clinical pipelines and outsourcing are boosting CDMO demand. Opportunities include scalable cell/vector production, non-viral platforms, automation and faster analytics.
- VirTus Respiratory Research LtdVirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 DataLONDON, August 26, 2026--VirTus Respiratory Research Ltd, a specialist respiratory contract research organisation (CRO), founded by Imperial College London investigators Professor Sebastian Johnston and Dr Michael Edwards, today highlighted its role in the preclinical development of Apollo Therapeutics’ and Imperial’s APL-10456, following the announcement of positive initial data from the vaccine’s Phase 1 clinical trial.
- Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's CognitionTokyo, Japan and Cambridge, UK, 26 August 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has received IND Acceptance from the U.S. Food and Drug Administration (FDA) for a Phase 2 study of NBI-1117567 (“NBI-’567”) for Alzheimer's cognition. Nxera will receive an IND Acceptance milestone payment of US$10 million from Neurocrine pursuant to the agreement. The milestone payment is expected to be recognised in full as revenue in Q3 FY2026. NBI-’567 is an investigational, orally administered, muscarinic M1 receptor preferring agonist discovered using Nxera’s proprietary NxWave™ drug discovery platform.
- Genezen4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector ManufacturingCommercial collaboration combines 4basebio's synthetic DNA technology with Genezen's viral vector development and manufacturing expertise to support gene therapy programs from early development through clinical and commercial manufacturing. CAMBRIDGE, United Kingdom and INDIANAPOLIS, Aug....
- WestBow PressNew book calls Christians to strengthen biblical discernment in an age of spiritual deception'The Devil In Bethel: How to Discern Satan's Demonic Teachers, Prophets, Idols, and Tools in God's Church' released — Christian clinical counselor Aaron G. Cisneros invites believers to take a closer look at biblical discernment in...
- FWD Group reports record profit amid continued growthFWD Group Holdings Limited (“FWD Group” or “FWD”) today announced interim results for the six months ended 30 June 2026[1]. - New business sales were up seven per cent on the prior corresponding period to US$1.35 billion on an annualised premium equivalent (APE) basis. New business contractual service margin was US$996 million, with year-on-year growth of 25 per cent. - Operating profit after tax was up 20 per cent to US$298 million with positive contributions from all four reportable segments: Hong Kong SAR & Macau SAR; Thailand & Cambodia; Japan; and Expansion Markets. Net profit after tax of US$172 million was a three-fold increase on the first half of 2025 and represents another record result. - Shareholder value creation indicators continued to trend positively, with comprehensive tangible equity up five per cent to US$8.83 billion and Group embedded value up five per cent to US$6.95 billion compared to 31 December 2025. FWD Group retained a solvency ratio[2] of 203 per cent, after the adoption of economic value-based solvency regulation in Japan. - Announced a key hire in May for the high-net-worth (HNW) business, which serves the global HNW insurance market with diversified asset allocation, wealth management, and legacy planning. - Received globally recognised certification in July for the development, procurement, deployment, and use of artificial intelligence (AI) systems, reflecting the growing maturity and responsible use of AI at FWD Group with the ISO/IEC 42001 standard achieved from the International Organisation for Standardisation/International Electrotechnical Commission. Huynh Thanh Phong, Group Chief Executive Officer and Executive Director of FWD Group, said, “FWD Group had a very strong start to our first full year as a listed company. Once again, we’ve demonstrated our ability to sustain growth, and to convert that growth into rising bottom-line profitability, while expanding margins. This was driven by the diversification built into our geographic footprint and multi-channel distribution model over the past 13 years, as well as a capital structure that positions FWD Group well for the future.” In the company’s home market of Hong Kong SAR, momentum continued despite record prior-year growth, supported by resilient domestic demand and the city’s role as one of the world’s largest cross-border wealth hubs. Excellent growth in Japan was driven by the company’s expansion into the savings and retirement needs segment in July 2025, complementing its existing protection business as a rapidly ageing society continues to fuel the longevity economy. In Thailand, the focus on profitable new business continued in the company’s market-leading exclusive bancassurance partnership with Siam Commercial Bank and agency distribution channels. The transition to a new Chief Executive Officer for Thailand was completed in May when Khun Knattapisit Krutkrongchai (KK) joined the company. Strong growth in Expansion Markets – comprised of Indonesia, Malaysia, the Philippines, Singapore, and Vietnam – was achieved despite the macroeconomic uncertainty in some countries in this segment. “These results are the latest example of the strong track record we’re building as a listed company serving more than 40 million customers across 10 markets in Asia. At FWD Group, we remain heavily focused on anchoring around the customer – aided by the golden age of transformational technological innovation that we’re living in,” added Huynh Thanh Phong. Across the region, 21 new products were introduced in the first half of 2026 in response to emerging customer needs. The FWD Group consumer outlook survey released in February 2026, prior to the outbreak of conflict in the Middle East and the associated global energy economic shocks, showed that most of Asia’s middle-class feel financially anxious and underprepared for retirement. About FWD Group FWD Group (1828.HK) is a pan-Asian life and health insurance business that serves over 40 million customers across 10 markets, including BRI Life in Indonesia. FWD’s customer-led and tech-enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience. Established in 2013, the company operates in some of the fastest-growing insurance markets in the world with a vision of changing the way people feel about insurance. FWD Group is listed on the Hong Kong Stock Exchange under the stock code 1828. For more information, please visit www.fwd.com For media inquiries, please contact: [email protected] Source: FWD Group Holdings Limited [1] The results are for the six months ended 30 June 2026 and are compared to the same period in 2025. Growth rates are represented on a constant exchange rate (CER) basis. The results are based on the unaudited interim condensed consolidated financial statements and embedded value supplementary report for the first half of 2026, unless otherwise stated. Operating profit after tax and net profit after tax represent the amounts attributable to equity holders of the company and are presented net of non-controlling interests. New business sales are calculated on an annualised premium equivalent (APE) basis, based on 100 per cent annualised first year premiums and 10 per cent single premiums. Group LCSM cover ratio, group embedded value and comprehensive tangible equity 2025 values are December 2025 balances/ratios and growth rates are shown accordingly. [2] Prescribed capital requirement (PCR) basis
- Concordare Trials Secures Funding Round to Accelerate Digitization of Clinical Trial ProtocolsNEW YORK, August 25, 2026--Concordare converts clinical trial protocols into a digital format, automating workflows that reduce the time, cost and error rate of clinical trials.
- SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced the grant of an inducement equity award to a new Senior Director, with a grant date of August 24, 2026. The award was granted in connection with the commencement of the Senior Director’s employment with the Company, as a material inducement to the employee’s acceptance of employment, and was approved in accordance with Nasdaq Listing Rule 5635(c)(4).